By Cort Johnson in Health Rising.
The PACE trial may, in the end, be about more than an injustice done to the chronic fatigue syndrome (ME/CFS) community. It may become, if the latest devastating criticism of it takes hold, exhibit number one in the medical community of how not to do a clinical trial.
It also presents a challenge to the orthodoxy of the medical profession. To think that a bunch of sick patients and a journalist working without pay could bring down an $8 million dollar study and embarrass one of the most respected medical journals in the world. It shouldn’t happen but with the latest critique emanating from a statistician one wonders how much time the PACE trial and Lancet have left.
To read the rest of this story, click on the link below: